These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28174325)

  • 1. Response by Sposato et al to Letter Regarding Article, "Effect of Right Insular Involvement on Death and Functional Outcome After Acute Ischemic Stroke in the IST-3 Trial (Third International Stroke Trial)".
    Sposato LA; Wardlaw JM; Hachinski V
    Stroke; 2017 Mar; 48(3):e92. PubMed ID: 28174325
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter by Alves et al Regarding Article, "Effect of Right Insular Involvement on Death and Functional Outcome After Acute Ischemic Stroke in the IST-3 Trial (Third International Stroke Trial)".
    Alves JN; Pinho J; Ferreira C
    Stroke; 2017 Mar; 48(3):e91. PubMed ID: 28174329
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter by Wu et al Regarding Article, "Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus".
    Wu C; Ma H; Ji X
    Stroke; 2019 Sep; 50(9):e271. PubMed ID: 31370768
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of Right Insular Involvement on Death and Functional Outcome After Acute Ischemic Stroke in the IST-3 Trial (Third International Stroke Trial).
    Sposato LA; Cohen G; Wardlaw JM; Sandercock P; Lindley RI; Hachinski V;
    Stroke; 2016 Dec; 47(12):2959-2965. PubMed ID: 27895298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letter by Behrouz et Al regarding article, "Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion".
    Behrouz R; Mutgi SA; Silver B
    Stroke; 2015 Jun; 46(6):e149. PubMed ID: 25899241
    [No Abstract]   [Full Text] [Related]  

  • 6. Response by Barreto and Grotta to Letter Regarding Article, "Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)".
    Barreto AD; Grotta JC
    Stroke; 2017 Sep; 48(9):e259. PubMed ID: 28754829
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter by Shah Regarding Article, "Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)".
    Shah NH
    Stroke; 2017 Sep; 48(9):e258. PubMed ID: 28754831
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter by Chao et al regarding article, "standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses".
    Chao AC; Po HL; Chan L
    Stroke; 2014 Dec; 45(12):e303. PubMed ID: 25342029
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to letter regarding article, "Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion".
    Coutts SB; Hill MD
    Stroke; 2015 Jun; 46(6):e150. PubMed ID: 25899240
    [No Abstract]   [Full Text] [Related]  

  • 10. Combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator for emergent revascularization in acute ischemic stroke (CLOTBUST-ER): design and methodology of a multinational phase 3 trial.
    Schellinger PD; Alexandrov AV; Barreto AD; Demchuk AM; Tsivgoulis G; Kohrmann M; Alleman J; Howard V; Howard G; Alexandrov AW; Brandt G; Molina CA;
    Int J Stroke; 2015 Oct; 10(7):1141-8. PubMed ID: 26120902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response by Spaander et al to Letter Regarding Article, "Sex Differences and Functional Outcome After Intravenous Thrombolysis".
    Spaander FH; Nederkoorn PJ;
    Stroke; 2017 Nov; 48(11):e330. PubMed ID: 28939670
    [No Abstract]   [Full Text] [Related]  

  • 12. Response by Spaander et al to Letter Regarding Article, "Sex Differences and Functional Outcome After Intravenous Thrombolysis".
    Spaander FH; Nederkoorn PJ;
    Stroke; 2017 Jul; 48(7):e175. PubMed ID: 28546327
    [No Abstract]   [Full Text] [Related]  

  • 13. Letter by Zedde et al Regarding Article, "Sex Differences and Functional Outcome After Intravenous Thrombolysis".
    Zedde M; Kremer C; Caso V
    Stroke; 2017 Jul; 48(7):e173-e174. PubMed ID: 28546323
    [No Abstract]   [Full Text] [Related]  

  • 14. Leukoaraiosis, Cerebral Hemorrhage, and Outcome After Intravenous Thrombolysis for Acute Ischemic Stroke: A Meta-Analysis (v1).
    Charidimou A; Pasi M; Fiorelli M; Shams S; von Kummer R; Pantoni L; Rost N
    Stroke; 2016 Sep; 47(9):2364-72. PubMed ID: 27491738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
    Kwiatkowski TG; Libman RB; Frankel M; Tilley BC; Morgenstern LB; Lu M; Broderick JP; Lewandowski CA; Marler JR; Levine SR; Brott T
    N Engl J Med; 1999 Jun; 340(23):1781-7. PubMed ID: 10362821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Worldwide reported use of IV tissue plasminogen activator for acute ischemic stroke.
    Berkowitz AL; Mittal MK; McLane HC; Shen GC; Muralidharan R; Lyons JL; Shinohara RT; Shuaib A; Mateen FJ
    Int J Stroke; 2014 Apr; 9(3):349-55. PubMed ID: 24207029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke.
    Saver JL; Goyal M; Bonafe A; Diener HC; Levy EI; Pereira VM; Albers GW; Cognard C; Cohen DJ; Hacke W; Jansen O; Jovin TG; Mattle HP; Nogueira RG; Siddiqui AH; Yavagal DR; Devlin TG; Lopes DK; Reddy V; du Mesnil de Rochemont R; Jahan R;
    Int J Stroke; 2015 Apr; 10(3):439-48. PubMed ID: 25777831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of tissue plasminogen activator in acute ischemic stroke.
    Hatcher MA; Starr JA
    Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter by Dai et al regarding article, "Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial".
    Dai Q; Sun W; Liu X
    Stroke; 2014 Jul; 45(7):e132. PubMed ID: 24916904
    [No Abstract]   [Full Text] [Related]  

  • 20. Response to letter regarding article, "standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses".
    Liao X; Wang Y; Wang Y
    Stroke; 2014 Dec; 45(12):e304. PubMed ID: 25342031
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.